Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)

Organon and Co410 enrolled

Overview

This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.

The duration of treatment is 10 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

410

Conditions

Hypercholesterolemia Coronary Disease

Interventions

MK0653, ezetimibeDRUG

Comparator: ezetimibe, placeboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with elevated cholesterol and coronary heart disease Exclusion Criteria: * Patients who do not meet specific cholesterol levels as required by the study

Outcomes

Primary Outcomes

Percentage of patients reaching LDL goal of <2.60 mmol/L after 6 weeks of treatment

Secondary Outcomes

Safety and tolerability.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.